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Targeting antioxidant pathways with
ferrocenylated N-heterocyclic carbene supported
gold(I) complexes in A549 lung cancer cells†
J. F. Arambula,*a R. McCall,a K. J. Sidoran,b D. Magda,c N. A. Mitchell,d
C. W. Bielawski,ef V. M. Lynch,g J. L. Sesslerg and K. Arumugam*h
Ferrocene containing N-heterocyclic carbene (NHC) ligated gold(I) complexes of the type [Au(NHC)2]
+
were prepared and found to be capable of regulating the formation of reactive oxygen species (ROS) via
multiple mechanisms. Single crystal X-ray analysis of bis(1-(ferrocenylmethyl)-3-mesitylimidazol-2-
ylidene)-gold(I) chloride (5) and bis(1,3-di(ferrocenylmethyl)imidazol-2-ylidene)-gold(I) chloride (6)
revealed a quasi-linear geometry around the gold(I) centers (i.e., the C–Au–C bond angle were
measured to be 177 and all the Au–Ccarbene bonds distances were in the range of 2.00 (7)–2.03 (1) A˚).
A series of cell studies indicated that cell proliferation inhibition and ROS generation were directly
proportional to the amount of ferrocene contained within the [Au(NHC)2]
+ complexes (IC50 of 6 < 5 <
bis(1-benzyl-3-mesitylimidazol-2-ylidene)-gold(I) chloride (4)). Complexes 4–6 were also confirmed to
inhibit thioredoxin reductase as inferred from lipoate reduction assays and increased chelatable
intracellular zinc concentrations. RNA microarray gene expression assays revealed that 6 induces
endoplasmic reticulum stress response pathways as a result of ROS increase.
1. Introduction
The regulation of reactive oxygen species (ROS) within biolog-
ical systems plays a vital role in the health and longevity of many
organisms.1,2 In disease states, such as cancer, the basal levels
of ROS are elevated due to increased cellular growth combined
with reduced waste elimination.3 Cellular adaptation to ROS in
pre-neoplastic cells exposed to inducers (i.e., hypoxia, metabolic
defects, ER stress, oncogene activation, etc.) oen result in
increased antioxidant pathway activity.4 Biological systems have
a host of natural defenses to ROS, including enzymes such
as superoxide dismutase (SOD), glutathione peroxidase, and
catalase. Additional cofactors, such as glutathione (GSH), thio-
redoxin (Trx)/thioredoxin reductase (TrxR), ascorbate (vitamin
C), and a-tocopherol (vitamin E), are also able to serve as ROS
scavengers.
Although cancer cells can thrive in the oxidative environ-
ment that they create, their ability to buffer ROS has limits. Both
tumor and normal cells are driven to apoptosis when ROS levels
become too high.5 This oxidative-stress pathway to apoptosis, if
exploited, could be a new cancer treatment option.4 While any
compound that disrupts redox homeostasis will negatively
affect all cells, normal cells are thought to have a greater
capacity for adaptation.4 Thus, it is expected that an agent that
acts to increase oxidative stress will overload the capabilities of
neoplastic cells, while being relatively less lethal to normal cells.
The chemotherapeutic development of agents that alter the
redox environment within cancer cells have been categorized
into (1) ROS generators (e.g., motexan gadolinium (MGd), b-
lapachone, etc.) and (2) antioxidant system inhibitors (e.g.,
buthionine sulphoximine, tetrathiomolybdate).6–14 Collectively,
data gleaned from this work have provided insight into the
cellular antioxidant system and has resulted in the proposal of
oxidative stress modulation as an anticancer strategy.4,15
Within the antioxidant system, Trx plays a central role in
mediating cellular response to environmental stress making the
inhibition of Trx/TrxR an attractive strategy for patients
undergoing radiation therapy.16,17 Studies with auranon (see
Fig. 1) revealed the ability of Au(I)-based compounds to inhibit
TrxR via binding to the selenylsulde/selenothiol redox center
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of the enzyme.18–22 This discovery resulted in the subsequent
development of NHC ligated Au(I) complexes as anticancer
therapeutic agents.23–30
While targeting antioxidant systems is a viable strategy for
anticancer development, there are limited examples of
complexes capable of affecting the cellular antioxidant system
via multiple mechanisms.31–37 To explore the possibility of
multiple modes of pathway targeting, we sought to develop
a complex capable of (1) TrxR inhibition and (2) redox cycling,
both of which would affect intracellular levels of ROS. Previous
reports of ferrocene-containing gold(I) complexes have indi-
cated activity against screened cancer cell lines; however, no
mechanistic investigations have been reported.38
It is known that ferrocene (Fc) complexes elevate ROS within
cancer cells and such complexes have become an increasingly
popular motif in the development of therapeutics for treating
cancer.39–48 One key feature of ferrocene is that it is capable of
undergoing a one electron oxidation to form the corresponding
ferrocenium cation (Fc2+/ Fc3+), a process that precedes the
reductive regeneration oen implicated in its cytotoxicity.41,49,50
These observations led us to hypothesize that a hybrid
compound capable of inducing non-specic ROS (via ferrocene)
in addition to selectively inhibiting TrxR (via binding to Au(I))
could override the ROS regulatory pathway in tumor models.51
To test this hypothesis, compounds 4–6 (cf., Fig. 1), which
contain (1) an Au(I) carbene core to inhibit TrxR and (2) ferro-
cene units designed to increase intracellular ROS levels were
prepared and tested in vitro against the A549, A2780, 2780CP,
and PC-3 cell lines. The underlying mechanism of action was
also explored.
2. Experimental
2.1 Materials and methods
The following compounds were prepared according to literature
procedures: 1-mesitylimidazole,52 [(Mes)(C3H3N2)(CH2C6H5)]
[Cl] (Mes ¼ mesityl),53,54 1-(ferrocenylmethyl)-3-mesitylimida-
zolium iodide,55 1,3-di(ferrocenylmethyl)imidazolium iodide,56
and (C4H2S)AuCl.57 All other reagents were purchased
from commercial sources and used as received, including:
[((CH3)3Si)2N]Na (NaHMDS) and [(Cp2Fe)CH2N(CH3)3][I] (Cp ¼
cyclopentadienyl). CDCl3, CD2Cl2, and DMSO-d6 (99.9%) were
purchased from Cambridge Isotope Laboratories, dried over 3 A˚
molecular sieves, and degassed using three consecutive freeze–
pump–thaw cycles prior to use. Solvents were either dried with
a solvent purication system from the Vacuum Atmosphere
Company (CH2Cl2, Et2O, hexanes and toluene) or freshly
distilled over 3 A˚ molecular sieves and degassed using three
consecutive freeze–pump–thaw cycles prior to use. All reactions
and manipulations were conducted under an atmosphere of
nitrogen unless otherwise indicated. UV-vis spectra were ob-
tained at ambient temperature with a Hewlett-Packard 8452A
diode array spectrophotometer. Molar absorptivities are re-
ported in M1 cm1. 1H and 13C NMR spectra were recorded on
JEOL 400 MHz spectrometer. Spectra were referenced to the
residual solvent as an internal standard, for 1H NMR: CD2Cl2,
5.32 ppm; CDCl3, 7.24 ppm; DMSO-d6, 2.50 ppm; for
13C NMR:
CD2Cl2, 54.00 ppm; CDCl3, 77.0 ppm, and DMSO-d6, 39.5 ppm.
Coupling constants (J) are expressed in hertz (Hz). High-reso-
lutionmass spectra (HRMS) were obtained using a VG analytical
ZAB2-E or a Karatos MS9 instrument (ESI or CI) and are re-
ported as m/z (relative intensity). Electrochemical measure-
ments were performed on a CHI660D or Pine Wavenow
electrochemical workstation using a silver wire quasi-reference
electrode, a platinum disk working electrode, and a Pt wire
auxiliary electrode in a gas tight three-electrode cell under an
atmosphere of nitrogen. Unless specied otherwise, the
measurements were performed using 1.0 mM solutions of the
analyte in dry DMSO with 0.1 M [N(nBu)4][PF6] as the electrolyte
and decamethylferrocene (Fc*) as the internal standard.
Differential pulse voltammetry measurements were performed
with 50 mV pulse amplitudes and 2 mV data intervals. All
potentials listed herein were determined by cyclic voltammetry
at 100 mV s1 scan rates and referenced to a saturated calomel
electrode (SCE) by shiing decamethylferrocene0/+ to 0.030 V
(DMSO).58,59 Elemental analyses were performed by Midwest
Microlab, LLC in Indianapolis, IN. Cell culture media consisted
of RPMI 1640 with 2 mM glutamine and 25 mM HEPES (Corn-
ing 10041CV) with 10% heat-inactivated fetal bovine serum
(Sigma f6178) and 1X penicillin-streptomycin (Sigma p4333).
Trypsin (Hyclone SH30236.01) and Dulbecco's Phosphate Buffer
Saline (Sigma d8537) were used for general cell maintenance
and harvesting. Cell lines were obtained from the ATCC (A549
and PC-3) and Prof. Zahid Siddik at MD Anderson (A2780 and
A2780CP). Thiazolyl Blue tetrazolium bromide (Alfa Aesar
L11939) was used for cell proliferation assays. Cell culture
plastic ware consisted of generic T-75 asks, 80.5 mm diameter
culture dishes, and treated 96-well plates.
2.2 Syntheses
Bis(1-benzyl-3-mesitylimidazol-2-ylidene)-gold(I) chloride
(4). An 8 mL screw cap vial equipped with a stir bar was charged
with [Mes(C3H3N2)CH2Ph]
+[Cl] (100 mg, 0.320 mmol) and
NaN(SiMe3)2 (64.5 mg, 0.035 mmol). Dry toluene (2 mL) was
added to the vial and the resulting mixture was stirred at 25 C
Fig. 1 Structures of ferrocene containing imidazolium salts (1–3,
previous work), their corresponding [Au(NHC)2]
+ complexes (4–6, this
work), and auranofin.
1246 | Chem. Sci., 2016, 7, 1245–1256 This journal is © The Royal Society of Chemistry 2016
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for 30 min. The reaction mixture was then ltered through
a plug of Celite into a 8 mL vial containing a slurry of (C4H8S)
AuCl (46.2 mg, 0.144 mmol) in 1 mL of dry toluene. The
resulting mixture was stirred at 25 C for 30 min. Aer the
volatiles were removed under reduced pressure, the resulting
crude product was dissolved in 2.5 mL of dichloromethane and
ltered through a plug of Celite into a 20 mL vial. The ltrate
was then treated with activated charcoal to remove colored
impurities. Aer ltering through a plug of Celite and tritura-
tion with hexanes (12mL), a white precipitate was obtained. The
precipitate was subjected to series of washes (3  3 mL of
hexanes and then 2  3 mL of diethyl ether) to yield a white
solid. The resulting crude product was recrystallized from
dichloromethane/diethyl ether to give colorless crystals. Yield:
43%. 1H NMR (d, CDCl3, 400 MHz): 1.79 (s, 12H, Mes-CH3), 2.23
(s, 6H, Mes-CH3), 5.17 (s, 4H, CH2), 6.82 (br s, 4H, Mes), 6.88 (br
s, 2H, PhNCH), 7.13 (m, 4H, Ph), 7.28 (m, 6H, Ph), 7.60 (s, 2H,
MesNCH). 13C NMR (d, CDCl3, 125 MHz): 17.67, 21.16, 54.35,
122.92, 123.10, 127.51, 128.48, 128.94, 129.21, 134.87, 135.99,
139.63, 184.18. HRMS (ESI) for [C38H40N4Au]
+ [M+] calcd
749.2919 found 749.2927. Anal. calcd for: C38H40N4AuCl: C,
58.13; H, 5.13; N, 7.14; found: C, 57.88; H, 5.32; N, 7.01.
Bis(1-(ferrocenylmethyl)-3-mesitylimidazol-2-ylidene)-gold(I)
chloride (5). An 8 mL screw cap vial equipped with a stir bar was
charged with [Fe(h5-C5H4CH2(C3H3N2)(Mes))Cp]
+[I] (100 mg,
0.196 mmol) and NaN(SiMe3)2 (43.3 mg, 0.236 mmol). Dry
toluene (2 mL) was added to the vial and the resulting mixture
was stirred at 25 C for 30 min. The reaction mixture was then
ltered through a plug of Celite into an 8 mL vial containing
a slurry of (C4H8S)AuCl (28.2 mg, 0.088 mmol) in 1 mL of dry
toluene. The resulting mixture was then stirred at 25 C for 20
min. Aer the volatiles were removed under reduced pressure,
the resulting crude product was dissolved with 2.5 mL of
dichloromethane and then ltered through a plug of Celite into
a 20 mL vial. The ltrate was then treated with activated char-
coal to remove colored impurities. Aer ltration and tritura-
tion with hexanes (12 mL), a yellow precipitate was obtained.
The yellow precipitate was subjected to series of washes (3  3
mL of hexanes and then 2  3 mL of diethyl ether) to yield
a yellow solid. Yield: 65%. 1H NMR (d, CDCl3, 400 MHz): 1.76 (s,
12H, Mes), 2.34 (s, 6H, Mes), 4.14 (s, 4H, Fc), 4.16 (s, 10H, Fc),
4.17 (s, 4H, Fc), 5.08 (s, 4H, CH2), 6.82 (s, 2H, FcNCH), 6.89 (s,
4H, Mes), 7.69 (s, 2H, MesNCH). 13C NMR (d, CDCl3, 125 MHz):
17.74, 21.33, 50.77, 68.65, 68.94, 69.05, 82.58, 122.47, 122.75,
129.27, 134.81, 134.88, 139.45, 183.20. HRMS (ESI) for C46H48-
N4Fe2Au [M]
+ calcd 965.2243, found 965.2253. Anal. calcd for:
C46H48N4Fe2AuCl: C, 55.19; H, 4.83; N, 5.60; found: C, 54.40; H,
5.62; N, 5.51.
Bis(1,3-di(ferrocenylmethyl)imidazol-2-ylidene)-gold(I) chlo-
ride (6). An 8 mL vial equipped with a stir bar was charged with
[Fe(h5-C5H4CH2(C3H3N2)(CH2-h
5-C5H4FeCp))Cp]
+[I] (100 mg,
0.170 mmol) and NaN(SiMe3)2 (38.7 mg, 0.211 mmol). Dry
toluene (2 mL) was added to the vial and the resulting mixture
was stirred at 25 C for 90 min. The reaction mixture was then
ltered through a plug of Celite into an 8 mL vial containing
a slurry of (C4H8S)AuCl (24.5 mg, 0.0764 mmol) in 1 mL of dry
toluene. The resulting mixture was then stirred at 25 C for 20
min. Aer the volatiles were removed under reduced pressure,
the resulting crude product was dissolved with 5 mL of
dichloromethane and ltered through a plug of Celite into a 20
mL vial. The ltrate was then treated with activated charcoal to
remove colored impurities. Aer ltration and trituration with
hexanes (12 mL), a yellow precipitate was obtained. The
resulting precipitate was subjected to series of washes (3 3mL
hexanes and then 2  3 mL diethyl ether), yielding a yellow
solid. The product was recrystallized from a mixture of
dichloromethane/methanol by treating with pentane, which
produced reddish brown crystals. Yield: 64%. 1H NMR (d, CDCl3
and CD3OD, 400 MHz): 4.18 (s, 20H, Fc), 4.22 (br s, 8H, Fc), 4.31
(s, 8H, Fc), 5.12 (s, 8H, CH2), 7.13 (s, 4H, N(CH)2N).
13C NMR (d,
CDCl3 and CD3OD, 125 MHz): 51.21, 69.02, 69.18, 82.06, 121.29,
182.13. HRMS [M]+ for [C50H48N4Fe4Au]
+, calcd 1125.0942,
found 1125.0951. Anal. calcd for: [C50H48N4Fe4Au][Cl0.5I0.5]: C,
49.78; H, 4.01; N, 4.64. Found: C, 49.77; H, 4.73; N, 4.65.
2.3 X-ray crystallography
Golden yellow crystals of 5 were obtained by diffusing diethyl
ether into a CH2Cl2 solution. Diffusing methyl tert-butyl ether
into a 1,2-dichloroethane solution provided bright yellow crys-
tals of 6. Data for 5 and 6 were collected on a Rigaku AFC12
diffractometer with a Saturn 724+ CCD using a graphite
monochromator with MoKa radiation (l ¼ 0.71073 A˚) equipped
with a Rigaku XStream cooling system (100 K). Data were
collected using 1 degree omega scans for both 5 and 6. For 5,
1560 frames were collected at 30 seconds per frame, while for 6,
1320 frames were collected at 40 seconds per frame. Data were
collected under control of the Rigaku Americas Corporation's
Crystal Clear version 1.40 (Rigaku Americas Corporation, 2008).
Structure solutions were obtained by direct methods for all
compounds using SIR 2004.60,61 Renements were accom-
plished by full-matrix least-squares procedures using the
SHELXL-2014 (G. M. Sheldrick, SHELXL/PC package (version
5.1), program for the renement of crystal structures, University
of Gottingen, 2003).62,63 In many instances, the cyclopentadienyl
rings on the ferrocenyl units displayed rotational disorder that
was generally treated with distance and angle constraints. Rigid
bond restraint was used in some instances to treat atoms
attached to the gold(I) center because some of the carbon atoms
bound to the gold(I) atom went non-positive denite. All
hydrogen atoms were added in calculated positions and
included as riding contributions with isotropic displacement
parameters tied to those of the atoms to which they were
attached. Additional crystallographic details may be found in
the respective CIFs, which were deposited at the Cambridge
Crystallographic Data Centre (CCDC), Cambridge, UK. For
CCDC numbers, please refer to the ESI.†
2.4 In vitro anti-proliferative activity
The proliferation of exponential phase cultures of A549 cells
was assessed by tetrazolium salt reduction. In brief, tumor cells
were seeded in 96-well microliter plates at 1000 cells per well
and allowed to adhere overnight in 100 mL RPMI 1640 medium
supplemented with 2 mM L-glutamine, 10% heat-inactivated
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 1245–1256 | 1247
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fetal bovine serum, and antibiotics (200 U cm3 penicillin and
200 mg cm3 streptomycin). Stock solutions of complex (10 mM
in DMSO or 5 mM in 50/50 v/v water/DMSO) were formulated
and then diluted in medium for secondary stocks of 100–200
mM depending on the complex being tested. Secondary stock
solutions were serially diluted in medium and immediately
added to wells, whereupon plates were incubated at 37 C under
a 5% CO2/95% air atmosphere. Aer a total of three days, a 50
mL aliquot of 3 mg mL1 tetrazolium dye, 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma
Chemical Co.), was added to each well, followed by a four hour
incubation period at 37 C. The medium was then removed, the
resulting formazan was dissolved in 50 mL DMSO and the
respective absorbances were measured at 560–650 nm using
a microplate reader (Molecular Devices, Sunnyvale, CA).
Absorbance values were corrected for background and then
normalized to wells containing untreated cells to allow for plate-
to-plate comparisons. The data are shown as mean inhibition of
proliferation or growth as a percentage of control cells and are
from 2–3 replicate experiments.
2.5 ICP-MS determination of Fe and Au
To determine complex uptake in tumor cell lines, ICP-MS
studies were undertaken using an A549 lung cancer cell line.
Cells were seeded in 150 cm2 cell culture asks and grown to
conuence in 30 mL RPMI 1640 medium supplemented with 2
mM L-glutamine, 10% heat inactivated fetal bovine serum, and
antibiotics (200 U cm3 penicillin and 200 mg cm3 strepto-
mycin). The media was removed and supplemented with 30 mL
of media (with FBS and antibiotics) containing 2.5 mM of
complex originating from 2.5 mM stock complex in DMSO. The
cells were then allowed to incubate at 37 C under a 5% CO2/
95% air atmosphere for 6 h. The medium from each sample was
then removed, and cells were washed with PBS (made in-house
with ICP-MS grade deionized water), treated with trypsin, and
pelleted in 15 mL conical tubes. The pellets were washed 2
with 10 mL of PBS and the cells were counted with a hemocy-
tometer. Cell counts consisted of 25–40 million cells per
sample. Samples were pelleted, frozen over dry ice, digested
with conc. HNO3, and analyzed by Applied Analytical, Inc. for
total Fe and Au content.
2.6 Determination of relative ROS levels through FACS
analysis
Tumor cells (2–3  106) were plated overnight and then incu-
bated with media containing one of the complexes described
above at concentrations of 2.5 mM. Control cells were treated
with vehicle only. At dened time-points, the media was
collected and the cells were washed with PBS. The PBS washing
was collected and the attached cells were treated with trypsin
and collected. The loosened cells were passed through a 40 mm
cell strainer. All media and washings were collected, pelleted by
centrifugation (3 min @ 300 g) and washed twice with cold PBS.
The cells were once again pelleted and suspended in PBS at
a nal concentration of 2  106 cells per mL. To each of the 15
mL centrifuge tubes was added 100 mL of the cell suspension
before being incubated in the dark at 37 C for 15 min at a nal
concentration of 1 mgmL1 CM-DCFA. PBS (2 mL) was added to
each sample. The cells were then pelleted, washed 2 with PBS,
and re-suspended in 5 mg mL1 of propidium iodide (PI) in PBS.
Control samples of unstained cells, cells stained with only CM-
DCFA, and cells stained with only PI were also prepared. Each
sample was added to one well of a 96-well plate. Samples were
then subjected to FACS analysis using a Millipore Guava easy-
Cyte 8 and analyzed using the Guava inCyte soware.
2.7 Lipoate reduction
To 96-well plates containing plateau phase A549 lung cells was
added 2.5 mM of each complex described above in RPMI-16
media containing 10% FBS and P/S. The cells were le to
incubate for 6 h at 37 C at 5% CO2. At this point, the media was
removed and replaced with HBSS buffer containing 20 mM
lipoate and 1 mM 5,50-dithiobis-2-nitrobenzoic acid (DTNB).
The plates were immediately monitored at 405 nm in a time
dependent fashion. Time points were collected every 20 min
and the T0 value was subtracted from each point.
2.8 Determination of intracellular Zn levels through FACS
analysis
The concentration of intracellular free zinc was assessed using
the ion-specic uorescent probe, FluoZin-3-AM (FluoZin-3,
Molecular Probes, Inc.) Plateau phase cultures grown in T-25
asks were treated with control vehicle or zinc acetate in the
presence or absence of 2.5 mM of a complex as described above
for 4 h. Aer treatment, the cells were washed with PBS and
treated with trypsin/EDTA for 5 min. Complete medium was
then added and the cells were isolated by centrifugation. Cell
pellets were washed and re-suspended in PBS. An aliquot of 1 
106 cells was removed, centrifuged, and re-suspended in 100 mL
of 20 mmol L1 FluoZin-3 in PBS. Aer a 25 min incubation
period under ambient conditions, the cells were washed twice
with PBS, re-suspended in 0.5 mL PBS, and then incubated for
20 min. An aliquot of the cell suspension was supplemented
with 2 mg mL1 propidium iodide (Sigma), incubated for 5 min,
and subjected to two-parameter ow cytometric analysis.
2.9 Isolation of RNA for microarray analysis
Ribonucleic acid was isolated for microarray analysis using the
QIAGEN RNeasy Plus Universal Mini Total RNA extraction
protocol. About 5 000 000 cells of A549 were seeded into each
cell culture dish (Corning 430293) with 11 mL RPMI 1640 with 2
mM L-glutamine, 10% heat-inactivated fetal bovine serum, 200
U cm3 penicillin, and 200 mg cm3 streptomycin. Each pair of
dishes was seeded from the same T-75 ask. Aer being incu-
bated overnight at 37 C with 5% CO2, another 11 mL of the
previously-described media were added to control dishes, while
treated dishes received 11 mL of 6 at a concentration of 5 mM in
the previously-described media, for a nal concentration of 2.5
mM. Aer incubating at 37 C with 5% CO2 for 6 h, the media
was removed by aspiration. The cells were washed with warm
PBS and then treated with trypsin. The trypsin was quenched
using complete medium and the cells were transferred into
1248 | Chem. Sci., 2016, 7, 1245–1256 This journal is © The Royal Society of Chemistry 2016
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
O
ct
ob
er
 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
6/
08
/2
01
6 
13
:5
9:
04
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
centrifuge tubes. The cells were centrifuged for 5 min at 1000
rpm in an Eppendorf 5804 centrifuge. The supernatant was
removed and cells were re-suspended in 380 mL PBS. Each
sample was then treated with 900 mL QIAzol Lysis Reagent, and
homogenized by vigorous vortexing and shaking. The QIAGEN
RNeasy Plus Universal Mini Total RNA protocol was then picked
up at Step 4. RNA was eluted in two volumes of 30 mL each for
a nal volume of 60 mL RNA. The centrifuges used include an
Eppendorf 5804R for steps performed at 4 C and an Eppendorf
MiniSpin Plus for steps performed at room-temperature. RNA
was stored at 80 C. The RNA concentration was measured
using a Thermo Scientic NanoDrop 2000c Spectrophotometer.
A gel of 1% agarose with in TAE was cast and RNA was run at
125 V for 60 min to ensure the integrity of the RNA through
visualization of ribosomal subunits. The ladder used was
the Thermo SM 1331 Generuler 1 kb + dsDNA ladder. Each
sample (400 ng + 3 mL) was submitted for microarray analysis to
the Interdisciplinary Center for Biotechnology Research at the
University of Florida.
3. Results and discussion
3.1 Syntheses and characterization
As shown in Fig. 2, compounds 4, 5, and 6 were synthesized
using a modied literature procedure by independently treating
free carbenes generated in situ with (C4H8S)AuCl.64 The result-
ing complexes were isolated as microcrystals aer titration of
the corresponding saturated CH2Cl2 solutions with n-hexanes,
followed by series of washes with n-hexanes and diethyl ether.
The complexes were subjected to a variety of characterization
techniques, including 1H NMR, 13C NMR and ultraviolet-visible
spectroscopy. The appearance of diagnostic 13C NMR signals
(Ccarbene) at 184.18 ppm (CDCl3), 183.20 ppm (CDCl3) and
182.13 ppm (CDCl3 and CD3OD) for 4, 5 and 6, respectively, were
consistent with the values reported for analogous Au–N-
heterocyclic carbene (NHC) complexes.38,65 Compounds 5 and 6
displayed a dipole-forbidden absorption band around 440 nm
and a shoulder at 528 nm, consistent with the values reported in
the literature for analogous ferrocene containing species (see
the ESI†). The aforementioned absorption bands were absent
for compound 4, consistent with the aforementioned assign-
ment. Single crystals of 5 suitable for X-ray diffraction analysis
were grown by slowly diffusing diethyl ether into a concentrated
CH2Cl2 solution. Similarly, single crystals of 6 were grown by
slowly diffusing methyl tert-butyl ether into a concentrated 1,2-
dichloroethane solution. Thermal ellipsoid plots of 5 and 6 are
presented in Fig. S1† and 2b, respectively. Compound 6 crys-
tallizes in the triclinic space group P1, while compound 5
crystallizes in the monoclinic space group C2/c. Compounds 5
and 6 adopted a linear geometry with C–Au–C bond angle
177. The N–C–N and C–Au–C bond angles were in accordance
with data reported for other analogous [Au(NHC)2]
+ gold(I)
complexes.38,65 All Au–Ccarbene bonds distances were in the range
2.00 (7)–2.03 (1) A˚.
To elucidate the electronic properties of compounds 2, 3, 5,
and 6, a series of electrochemical measurements were carried
out in DMSO with [N(nBu4)][PF6] as the electrolyte; key data are
summarized in Table 1. Compounds 2, 3, 5, and 6 all displayed
an iron centered (Fe2+/ Fe3+) reversible oxidations. One elec-
tron oxidations for 2 and 3 was observed at 0.59 V (vs. SCE),
whereas the relatively electron rich [Au(NHC)2]
+ complexes
underwent oxidation at 0.56 V. No gold oxidation was
observed under the experimental conditions employed.
Fig. 2 (a) Synthesis of ferrocene containing Au(I) carbene complexes.
(b) ORTEP diagram of 6 rendered using POV-Ray. Thermal ellipsoid
plots are drawn at the 50% probability level. Hydrogen atoms and
counter anion are omitted for clarity. Selected bond lengths (A˚) and
angles (deg): C1–N1, 1.37(1); C1–N2, 1.35(2); C1–Au1, 2.021(9); C26–
Au1, 2.028(8); C26–N3, 1.33(1); C26–N4, 1.35(1); N1–C1–N2, 105.2(8);
N3–C26–N4, 105.1(7); C1–Au1–C26, 176.5(3).
Table 1 Electrochemical data recorded for various ferrocenylated
complexesa
Compound E1/2
a (V)
2 0.58 (r)
3 0.59 (r)
5 0.56 (r)
6 0.57 (r)
a The potentials shown were obtained via differential pulse voltammetry
measurements in DMSO with 0.1 M [N(nBu)4]
+[PF6]
 electrolyte, 0.1 mM
analyte, and referenced vs. SCE. See the ESI for the corresponding cyclic
voltammograms and differential pulse voltammograms. r ¼ reversible.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 1245–1256 | 1249
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3.2 Ability to inhibit cell proliferation
To assess the ability, if any, of the individual complexes of this
study to inhibit cell growth, cell proliferation assays were con-
ducted following exposure of A549 lung cells to 2–6 and
a control compound, auranon; key data are summarized in
Table 2. Typical dose–response curves were observed with all
complexes investigated (cf. Fig. 3a). It was observed that potency
was directly proportional to amount of ferrocene contained
within the complex (i.e., IC50 of 6 < 5 < 4). The potency of 6 (IC50
¼ 0.14  0.03 mM) was found to be >10 fold greater than aur-
anon (IC50 ¼ 1.67  0.05 mM) in this cell line. In addition, it
was found that the Au-containing complexes displayed signi-
cantly greater potency (>100-fold) than the individual ferrocene
subunits (i.e., compounds 2 and 3). To assess the contribution
of each moiety of 6 to the observed cell proliferation inhibitory
effects, A549 cells were exposed to variable concentrations of 3 +
4 and auranon + 3, both in a 1 : 2 molar ratio, and compared to
6. A combined dose of [Au(NHC)2]
+ 4 and ferrocene 3 provided
a slight synergistic effect (i.e. IC50 ¼ 0.61  0.05 mM vs. 0.71 
0.03 mM), while mixtures of auranon and 3 provided no
improvement. Regardless, the ability of 6 to inhibit cell prolif-
eration was still signicantly greater than the sum of its
constituent parts (c.f. Fig. 3b).
Previous studies had indicated an increase in the potency of
ferrocenium relative to ferrocene.26 To test if this relationship
was relevant to the complexes described above, 5 was oxidized
to [5][BF4]2 and examined for its ability to inhibit cell prolifer-
ation of A549 lung cells. The oxidized ferrocenium compound
([5][BF4]2) was tested in conjunction with 5 and no difference
was observed in its ability to inhibit A549 cell growth (see ESI†).
Complex 6 was further screened with PC-3 prostate (p53
null), A2780 (wt-p53 platinum sensitive), and 2780CP (wt-p53
isogenic partner to A2780 displaying multidrug resistance
(MDR)) (see Table 3).66,67 Inspection of the IC50 values indicated
similar potencies across all cell lines with no observed resis-
tance in 2780CP relative to A2780 cell lines.
3.3 Assessing cellular uptake via ICP-MS
To assess complex integrity and uptake, inductively coupled
plasma mass spectrometry (ICP-MS) studies were carried out
with the goal of quantifying Fe and Au levels. In brief, A549 cells
were independently exposed to 2.5 mM of 6 or 3 for 6 h. Cells
were then collected, counted, and quantied for intracellular
uptake of Fe and Au via ICP-MS (cf. Fig. 4). An increase in Fe was
evident in both samples treated with 6 as well as 3. Relative to 3,
Fe was quantied as 11-fold higher in cells aer exposure to 6.
This result suggested to us that cellular uptake of 6 was 5.6-fold
higher than that of 3 in A549 lung cancer cells and is consistent
with the 100-fold difference observed in the ability of 6 to
inhibit cell proliferation. Gold was also detected in cells
exposed to 6. Subsequent analysis resulted in a 4 : 1 ratio of
Fe : Au in cells exposed to 6, indicative that the [Au(NHC)2]
+
complex is stable and enters the cell as a whole complex.
3.4 Reactive oxygen species disruption
It is proposed that the combination of ferrocene moieties and
Au–NHC complexes present in the compounds of this study
results in a system that is capable of disrupting ROS regulation
via multiple mechanisms. To assess the ability of the aforemen-
tioned complexes to disrupt and increase ROS levels, uorescence
assisted cell-sorting (FACS) analyses were conducted utilizing 5-
(and-6)-chloromethyl-20,70-dichlorodihydrouorescein diacetate,
acetyl ester (CM-H2DCFDA), a uorescein based indicator for
Fig. 3 (a) Cell proliferation profiles and (b) bar graph plot summarizes
the potency of all the compounds explored. Note that the potency of 6
is greater than the 2 : 1 mixture of compounds 3 and 4. Error bars
represent one standard deviation. A one-way ANOVA with Dunnet's
post-hoc test was used to compare each compound with auranofin
(*P < 0.05; **P < 0.01).
Table 2 IC50 values for compounds tested on A549 lung cancer cells
Complex IC50 (mM)
a Complex IC50 (mM)
2 6.4  1.1 6 0.14  0.03
3 13  1.5 Auranon (A) 1.67  0.05
4 0.71  0.03 3 + 4 0.61  0.05
5 0.39  0.01 Auranon (A) + 3 1.61  0.09
a Standard deviation is noted (3–5 repeat runs).
Table 3 IC50 values for compound 6 in various cancer cell lines
Cell line A549 lung A2780 ovarian 2780CP ovarian PC-3 prostate
IC50 (mM)
a 0.14  0.03 0.19  0.01c 0.12  0.01c 0.48  0.15b
a Standard deviation is noted (3–5 repeat runs). b A Dunnet's post-hoc
test revealed that the IC50 for compound 6 was only different in PC-3
cells. c Tukey's test was used to verify that the potency of compound 6
was equal in the A2780 and A2780CP cell lines.
1250 | Chem. Sci., 2016, 7, 1245–1256 This journal is © The Royal Society of Chemistry 2016
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general ROS uctuations. Due to the relatively high potencies of
the [Au(NHC)2]
+ complexes studied, low drug incubation
concentrations were needed to avoid cellular stress. A549 cells
were thus exposed to variable concentrations of complex 5
for 4 hours, collected and treated with propidium iodide (PI)
to assess cytotoxicity. It was found that a concentration of
2.5 mM of [Au(NHC)2]
+ was sufficient to allow for exposure
without killing cells within the 4 hour incubation period (see
the ESI†).
Complexes 4, 5, 6 and auranon were independently added
to A549 cells and their ability to increase ROS was examined (cf.
Fig. 5). It was found that while all of the complexes induced an
ROS increase relative to control samples, complexes 4, 5, and 6
provided higher levels than that observed when auranon was
utilized. The greatest increase in ROS was detected in cells
exposed to complex 6, which provided a 14-fold increase in ROS
relative to cells treated with vehicle.
As previously mentioned, L-buthionine-(S,R)-sulfoximine
(BSO) acts as a selective inhibitor of GSH synthesis.25,68,69 The
down regulation of GSH, a ROS scavenger, could potentiate the
effects of the gold complexes of this study, thus providing
support for the proposed mode of action.70 To test this
hypothesis, A549 cells were exposed to BSO for a 24 h period
before being independently treated with [Au(NHC)2]
+ complexes
4, 5, 6 or auranon (cf. Fig. 5). It was observed that cells with
reduced levels of GSH provided increased levels of ROS upon
exposure to the various Au(I)-containing complexes of this
study.
3.5 Inhibition of thioredoxin reductase
It has previously been reported that auranon and [Au(NHC)2]
+
are able to bind to and inhibit TrxR, a feature considered inte-
gral to their mode of cytotoxic action.23–26 This literature
suggestion, combined with our ndings that L-buthionine-(S,R)-
sulfoximine (BSO) treatments (a GSH inhibitor) sensitizes A549
cells towards increases in ROS production when independently
exposed to 4, 5, or 6, led us to investigate whether these
complexes would also have an effect on the thioredoxin
pathway. The live cell measurement of thioredoxin reductase
activity may be accomplished by monitoring the reduction of
the oxidized form of the cell-permeable cofactor lipoate to its
reduced form, dihydrolipoate. To this effect, the plateau phase
A549 cells were independently exposed to 2.5 mM treatments of
[Au(NHC)2]
+ 4–6, auranon and 2 or 3 for 6 h. Aer treatment,
the cells were thenmonitored colorimetrically for their ability to
reduce lipoate (cf. Fig. 6). It was observed that the A549 cells
treated with auranon provided a 70% reduction in TrxR
activity relative to samples treated with vehicle. Thioredoxin
reductase inhibition in cells independently treated with
[Au(NHC)2]
+ complexes 4–6 was found to also be signicant and
ranged from 55–60% inhibition. A more modest (i.e., 10–15%)
inhibition was observed in cells treated with 2 or 3. These
results were taken as evidence that complexes 4–6 are capable of
TrxR inhibition similar to that of auranon (a positive control).
This mechanism is thought to contribute, in part, to the potency
observed in complexes containing both [Au(NHC)2]
+ and
ferrocene.
Fig. 4 ICP-MS detection of intracellular Fe and Au levels from A549
cells treated with compounds 3 and 6. Error bars represent one
standard deviation. Although a biological trend is evident, statistical
analysis (i.e., one-way ANOVA) resulted in a P value of 0.09. This result
may be explained by our small sample size (N ¼ 2).
Fig. 5 Reactive oxygen species detected by fluorescent signal
increases of DCF via flow cytometric analysis in live A549 cells treated
with various complexes. H2O2 was used as a positive control. Error bars
represent one standard deviation. A one-way ANOVA with Dunnet's
post-hoc test was used to compare each compound with the vehicle
control (*P < 0.05; **P < 0.01).
Fig. 6 Time-dependent inhibition of thioredoxin reductase (TrxR) via
the reduction of lipoate. Error bars represent standard deviation. For
clarity, statistical symbols were not included in this figure. A one-way
ANOVAwith Dunnet's post-hoc test was used to compare TrxR activity
at the 180 minute time point. At this time point, all compounds were
statistically different from the control (P < 0.05: 2 and 3; P < 0.001:
auranofin, 4, 5, and 6) and auranofin (P < 0.05: 5 and 6; P < 0.001: 2, 3,
and 4) in their ability to inhibit TrxR.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 1245–1256 | 1251
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3.6 Intracellular free zinc elevation
The above ndings suggested to us that the complexes 4–6 can
weaken the antioxidant system in different ways. ROS increases
could affect reducing species containing vicinal thiols bound to
zinc, such as metallothionein. This, in turn, would produce
intracellular zinc as an additional by-product of redox cycling.
To test this hypothesis, cultures of A549 cells were indepen-
dently incubated with [Au(NHC)2]
+ complexes 4–6, auranon, or
2 or 3 for 6 hours. At that point, FACS analysis was used to detect
(chelatable) intracellular zinc with the ion-specic dye, FluoZin-
3 (cf. Fig. 7).71 It was found that complexes 4–6 induced the
greatest amount of zinc increase, with 6 providing the most
substantial elevation in free zinc (i.e., a 5-fold increase). A
moderate 2–3 fold increase in Zn was detected in live cells
treated with 2 or 3, while no Zn increase was detected in
samples treated with auranon. Upon co-treatment with 100
mM zinc acetate, a signicant increase (i.e. 45-fold) in intracel-
lular zinc was detected in cells treated with complexes 4–6,
whereas little to no change was detected in auranon, 2, or 3
(see the ESI†). In addition, upon further study, little to no
synergistic effect between 6 and Zn was detected in cell prolif-
eration assays (see the ESI†).
3.7 Gene expression in treated A549 cells
To assess the effects of the complexes on gene expression
proles, total cellular RNA was isolated from plateau phase
A549 cultures treated with 2.5 mM complex 6 for 6 h in triplicate
and analyzed on RNA microarrays.72,73 These conditions were
chosen based on the consideration that no cell death by 6 was
observed within 6 h of treatment. All 740 transcripts (including
control and non-coding genes) that were differentially
expressed (up-regulation: >1.4-fold, down-regulation: <0.7-fold,
corrected P < 0.15) in response to treatment with 6 are presented
(see the ESI†). For clarity, a list of coding transcripts that were
most differentially expressed is listed in Table 4. As one might
anticipate, transcripts with cell death/growth/survival-related
Fig. 7 Detection of intracellular zinc fluctuations by fluorescent signal
increases of FluoZin-3 via flow cytometric analysis in live A549 cells
treated with various complexes. Error bars represent one standard
deviation. A one-way ANOVA with Dunnet's post-hoc test was used to
compare each compound with the vehicle control (**P < 0.01).
Table 4 RNA microarray analysis: differential expression of select genes in A549 cells treated with 6
Gene ID Gene symbol Gene description FC P-value
79094 CHAC1 ChaC, cation transport regulator homolog 1 5.56 1.19205  107
1649 DDIT3 DNA-damage-inducible transcript 3 4.43 4.30297  109
57761 TRIB3 Tribbles pseudokinase 3 (TRIB3) 4.41 6.5417  108
440 ASNS Asparagine synthetase (glutamine-hydrolyzing) 3.94 3.28201  108
27063 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle) 3.90 0.000102275
9518 GDF15 growth differentiation factor 15 2.90 9.19533  106
7779 SLC30A1 Solute carrier family 30 (zinc transporter) 2.86 0.002992119
23645 PPP1R15A Protein phosphatase 1, regulatory subunit 15A 2.79 7.03697  107
7436 VLDLR Very low density lipoprotein receptor 2.56 3.7443  106
9709 HERPUD1 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like
domain
2.48 2.53382  107
2081 ERN1 Endoplasmic reticulum to nucleus signaling 1 2.44 1.02427  106
3162 HMOX1 Heme oxygenase (decycling) 1 2.41 6.63288  105
4495 MT1G Metallothionein 1G 2.24 0.034444693
467 ATF3 Activating transcription factor 3 2.10 1.231  106
16 AARS Alanyl-tRNA synthetase 2.03 3.39778  106
2920 CXCL2 Chemokine (C-X-C motif) ligand 2 1.93 0.00014337
4490 MT1B Metallothionein 1B 1.92 0.032952383
3576 CXCL8 Chemokine (C-X-C motif) ligand 8 1.92 1.10178  105
7494 XBP1 X-box binding protein 1 1.87 3.60972  105
4496 MT1H Metallothionein 1H 1.77 0.025658976
3311 HSPA7 Heat shock 70 kDa protein 7 1.63 0.008645638
6782 HSPA13 Heat shock protein 70 kDa family, member 13 1.54 0.001471724
3309 HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) 1.51 2.83009  105
29948 OSGIN1 Oxidative stress induced growth inhibitor 1 1.48 0.000144965
57181 SLC39A10 Solute carrier family 39 (zinc transporter), member 10 0.63 0.016893383
3306 HSPA2 Heat shock 70 kDa protein 2 0.56 1.49155  105
6347 CCL2 Chemokine (C-C motif) 0.39 1.53404  105
1252 | Chem. Sci., 2016, 7, 1245–1256 This journal is © The Royal Society of Chemistry 2016
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functions (e.g., DDIT3, SESN2, and GDF15) were identied. The
list also includes transcripts involved in endoplasmic reticulum
stress/response to stress (i.e. CHAC1, DDIT3, TRIB3, ASNS, etc.),
HIF-1 (i.e., HMOX1), zinc transport (SLC30A1), metallothioneins
(MT; ve metallothionein related transcripts), and heat shock
transcription factors (HSF; e.g., four heat shock-related
transcripts).
4. Discussion
A series of ferrocene containing [Au(NHC)2]
+ complexes were
designed as models for dual targeting of specic pathways. The
ferrocene and [Au(NHC)2]
+ moieties were specically chosen to
(1) generate intracellular ROS non-selectively and (2) selectively
inhibit TrxR, an enzyme essential in the ROS response pathway.
We chose to explore this binary approach as a novel way to
target and overwhelm specic pathways. Disruption of ROS
regulatory systems is attractive in the context of drug design due
to the fact that cancers typically display elevated ROS levels.15
While cancer selectivity (i.e., healthy tissue vs. tumors) has yet to
be established in the present instance, it is evident that there is
a positive correlation between ROS generation and the ability of
a drug candidate to inhibit cell proliferation. We were able to
successfully show an increase in ROS generation that was both
positively correlated with the number of ferrocene subunits
incorporated in the complex, and an ability to inhibit cell
proliferation (i.e., for 6, IC50 ¼ 0.14 mM, 13.7-fold increase of
intracellular ROS). This is a signicant increase in potency
relative to the control compound auranon (IC50¼ 1.67 mM, 2.7-
fold increase in ROS) whose primary mode of action involves
TrxR inhibition.18–20,22–26 Downregulation of GSH by pre-treat-
ment with BSO was found to potentiate the effects of all
complexes, thus providing support for the proposed mode of
action.70
A key nding to emerge from this study is that the potency of
6 is greater than the sum of its parts (i.e., its antiproliferative
activity that is greater than that of 3 + 4). It was experimentally
conrmed via ICP-MS analyses that the intracellular uptake of 6
was greater than that of 3, and may reect increased ferrocene
delivery through the action of the [Au(NHC)2]
+ complex. The
difference in uptake between 6 and 3 could also reect the
altered amphiphilicity of 6 relative to 3. It may be inferred that
the reduced potency of 3 (or any combination of complexes that
include 3) may be due to poor cellular uptake and not a lack of
ferrocene activity. However, a key point is that the potency of
complex 6 is multifactorial and cannot be accounted for solely
in terms of the number of ferrocene units it contains.
As would be expected in light of the proposed dual targeting
mode of action, the present [Au(NHC)2]
+ complexes were found
to inhibit TrxR. Complexes 4, 5, and 6 were found to inhibit
55% of TrxR activity, while auranon inhibited activity by
70%. This difference in inhibition may be due to differences
in the coordination chemistry of [Au(NHC)2]
+ carbene (i.e., 6)
and Au(I)–phosphine complexes (i.e. auranon). The signi-
cant increase in ROS and inhibition of TrxR by the ferroce-
nylated [Au(NHC)2]
+ complexes was further corroborated by
an intracellular increase in free zinc (also indicative of ROS
increase/stress response).
RNA microarray gene expression was used to elucidate
further the mechanism of 6. Of the 279 genes that were differ-
entially expressed, a signicant number were associated with
apoptosis and cell cycle arrest, as might be expected. Gene
Ontology (GO) analyses of the transcripts that were differen-
tially-regulated in response to exposure to compound 6 were
performed to investigate cellular responses to this complex.
Intriguingly, ER stress and oxidative stress response genes were
found to be enriched in this analysis (see Table 4 and S2†).
These data, coupled with the differential expression of HMOX1
(containing an antioxidant response element in its promoter)
and OSGIN1 (an oxidative response protein that regulates cell
death), were taken as an indication that the oxidative stress
induced by 6 results in ER stress. The subsequent upregulation
of SLC30A1, downregulation of SLC39A10 (both Zn transporters)
and upregulation of multiple metallothioneins are thought to
reect a response to ROS stress since they serve to attenuate an
increase in intracellular zinc concentrations. The role intracel-
lular free (non-protein bound) zinc plays in regulating cellular
functions is of considerable relevance to cancer. For example,
increased free zinc concentration has been proposed to stabilize
hypoxia-inducible factor-1 (HIF-1) and thus inuence processes
such as glycolysis, apoptosis, and angiogenesis.74–77 Moreover,
free zinc inhibits thioredoxin reductase,72 a key mediator in the
cellular response to oxidative stress that is frequently overex-
pressed in cancer.78–80
The scope of activity of gold complex 6 was further evaluated
within a limited panel of cancer cell lines PC3 prostate (p53
null), A2780 ovarian (wt-p53 platinum sensitive), and 2780CP
(wt-p53 isogenic partner to A2780 displaying multidrug resis-
tance (MDR)) displaying varying p53 status and drug resistance.
From these results, it should be noted that there was no
observed resistance in 2780CP relative to A2780 cell lines. This
result is considered signicant in that small molecular plat-
inum containing species oen display 2–27 fold resistance
between this isogenic pair.66,67
5. Conclusions
Herein we report that ferrocenylated N-heterocyclic carbene
supported Au(I) complexes are capable of targeting antioxidant
pathways by regulating ROS via multiple mechanisms. The
proposed incorporation of ROS-generating ferrocenes on a Au(I)
platform capable of TrxR inhibition provided complexes with
enhanced anti-proliferative properties relative to ferrocene or
Au(I) alone (e.g., auranon or 4). It also provides initial “proof-
of-principle” support for the suggestion that it is useful to
address key cancer-related pathways via multiple modes of
targeting. The utility of complex 6, for example, in treating
potential cross-resistance across a number of cell lines is also
appealing. Accordingly, further mechanistic studies, tests of
toxicity and efficacy in mammalian models, as well as efforts to
prepare and test second-generation complexes that are able to
accentuate ROS effects viamultiple pathways are underway. The
results of these efforts will be presented in due course.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 1245–1256 | 1253
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